O	0	7	Primary
O	8	16	analysis
O	17	19	of
O	20	21	a
O	22	33	prospective
O	33	34	,
O	35	45	randomized
O	45	46	,
O	47	53	single
O	53	54	-
O	54	61	blinded
O	62	67	phase
O	68	70	II
O	71	76	trial
O	77	87	evaluating
O	88	91	the
B-intervention	92	96	HER2
I-intervention	97	104	peptide
I-intervention	105	109	AE37
I-intervention	110	117	vaccine
O	118	120	in
O	121	127	breast
O	128	134	cancer
O	135	143	patients
O	144	146	to
O	147	154	prevent
B-condition	155	165	recurrence
O	165	166	.

O	167	171	AE37
O	172	174	is
O	175	178	the
O	179	181	Ii
O	181	182	-
O	182	185	Key
O	186	192	hybrid
O	193	195	of
O	196	199	the
O	200	203	MHC
O	204	209	class
O	210	212	II
O	213	220	peptide
O	220	221	,
O	222	226	AE36
O	227	228	(
O	228	232	HER2
O	233	235	aa
O	235	236	:
O	236	239	776
O	239	240	-
O	240	243	790
O	243	244	)
O	244	245	.

O	246	251	Phase
O	252	253	I
O	254	261	studies
O	262	268	showed
O	269	273	AE37
O	274	286	administered
O	287	291	with
O	292	303	granulocyte
O	304	314	macrophage
O	315	321	colony
O	321	322	-
O	322	333	stimulating
O	334	340	factor
O	341	342	(
O	342	344	GM
O	344	345	-
O	345	348	CSF
O	348	349	)
O	350	352	to
O	353	355	be
O	356	360	safe
O	361	364	and
O	365	371	highly
O	372	383	immunogenic
O	383	384	.

O	385	386	A
O	387	398	prospective
O	398	399	,
O	400	410	randomized
O	410	411	,
O	412	423	multicenter
O	424	429	phase
O	430	432	II
O	433	441	adjuvant
O	442	447	trial
O	448	451	was
O	452	461	conducted
O	462	464	to
O	465	473	evaluate
O	474	477	the
O	478	485	vaccine
O	485	486	'
O	486	487	s
O	488	496	efficacy
O	496	497	.

B-eligibility	498	508	Clinically
I-eligibility	509	516	disease
I-eligibility	516	517	-
I-eligibility	517	521	free
I-eligibility	522	526	node
I-eligibility	526	527	-
I-eligibility	527	535	positive
I-eligibility	536	539	and
I-eligibility	540	544	high
I-eligibility	544	545	-
I-eligibility	545	549	risk
I-eligibility	550	554	node
I-eligibility	554	555	-
I-eligibility	555	563	negative
I-eligibility	564	570	breast
I-eligibility	571	577	cancer
I-eligibility	578	586	patients
I-eligibility	587	591	with
I-eligibility	592	598	tumors
I-eligibility	599	609	expressing
I-eligibility	610	613	any
I-eligibility	614	620	degree
I-eligibility	621	623	of
I-eligibility	624	628	HER2
I-eligibility	629	630	[
I-eligibility	630	650	immunohistochemistry
I-eligibility	651	652	(
I-eligibility	652	655	IHC
I-eligibility	655	656	)
I-eligibility	657	658	1
I-eligibility	658	659	-
I-eligibility	659	660	3
I-eligibility	660	661	+
I-eligibility	661	662	]
O	663	667	were
O	668	676	enrolled
O	676	677	.

O	678	686	Patients
O	687	691	were
O	692	702	randomized
O	703	705	to
O	706	710	AE37
O	711	712	+
O	713	715	GM
O	715	716	-
O	716	719	CSF
O	720	726	versus
B-control	727	729	GM
I-control	729	730	-
I-control	730	733	CSF
I-control	734	739	alone
O	739	740	.

O	741	749	Toxicity
O	750	753	was
O	754	763	monitored
O	763	764	.

O	765	773	Clinical
O	774	785	recurrences
O	786	790	were
O	791	801	documented
O	802	805	and
O	806	813	disease
O	813	814	-
O	814	818	free
O	819	827	survival
O	828	829	(
O	829	832	DFS
O	832	833	)
O	834	842	analyzed
O	842	843	.

O	844	847	The
O	848	853	trial
O	854	862	enrolled
B-total-participants	863	866	298
O	867	875	patients
O	875	876	;
B-intervention-participants	877	880	153
O	881	889	received
O	890	894	AE37
O	895	896	+
O	897	899	GM
O	899	900	-
O	900	903	CSF
O	904	907	and
B-control-participants	908	911	145
O	912	920	received
O	921	923	GM
O	923	924	-
O	924	927	CSF
O	928	933	alone
O	933	934	.

O	935	938	The
O	939	945	groups
O	946	950	were
O	951	955	well
O	956	963	matched
O	964	967	for
O	968	985	clinicopathologic
O	986	1001	characteristics
O	1001	1002	.

O	1003	1013	Toxicities
O	1014	1018	have
O	1019	1023	been
O	1024	1031	minimal
O	1031	1032	.

O	1033	1035	At
O	1036	1039	the
O	1040	1044	time
O	1045	1047	of
O	1048	1051	the
O	1052	1059	primary
O	1060	1068	analysis
O	1068	1069	,
O	1070	1073	the
B-outcome	1074	1084	recurrence
I-outcome	1085	1089	rate
O	1090	1092	in
O	1093	1096	the
O	1097	1107	vaccinated
O	1108	1113	group
O	1114	1117	was
B-iv-bin-percent	1118	1120	12
I-iv-bin-percent	1120	1121	.
I-iv-bin-percent	1121	1122	4
I-iv-bin-percent	1122	1123	%
O	1124	1130	versus
B-cv-bin-percent	1131	1133	13
I-cv-bin-percent	1133	1134	.
I-cv-bin-percent	1134	1135	8
I-cv-bin-percent	1135	1136	%
O	1137	1139	in
O	1140	1143	the
O	1144	1151	control
O	1152	1157	group
O	1158	1159	[
O	1159	1167	relative
O	1168	1172	risk
O	1173	1182	reduction
O	1183	1185	12
O	1185	1186	%
O	1186	1187	,
O	1188	1190	HR
O	1191	1192	0
O	1192	1193	.
O	1193	1196	885
O	1196	1197	,
O	1198	1200	95
O	1200	1201	%
O	1202	1212	confidence
O	1213	1221	interval
O	1222	1223	(
O	1223	1225	CI
O	1225	1226	)
O	1227	1228	0
O	1228	1229	.
O	1229	1232	472
O	1232	1233	-
O	1233	1234	1
O	1234	1235	.
O	1235	1238	659
O	1238	1239	,
O	1240	1241	P
O	1242	1243	=
O	1244	1245	0
O	1245	1246	.
O	1246	1248	70
O	1248	1249	]
O	1249	1250	.

O	1251	1254	The
O	1255	1261	Kaplan
O	1261	1262	-
O	1262	1267	Meier
O	1268	1277	estimated
B-outcome	1278	1279	5
I-outcome	1279	1280	-
I-outcome	1280	1284	year
I-outcome	1285	1288	DFS
I-outcome	1289	1293	rate
O	1294	1297	was
B-iv-bin-percent	1298	1300	80
I-iv-bin-percent	1300	1301	.
I-iv-bin-percent	1301	1302	8
I-iv-bin-percent	1302	1303	%
O	1304	1306	in
O	1307	1317	vaccinated
O	1318	1324	versus
B-cv-bin-percent	1325	1327	79
I-cv-bin-percent	1327	1328	.
I-cv-bin-percent	1328	1329	5
I-cv-bin-percent	1329	1330	%
O	1331	1333	in
O	1334	1341	control
O	1342	1350	patients
O	1350	1351	.

O	1352	1354	In
O	1355	1362	planned
O	1363	1369	subset
O	1370	1378	analyses
O	1379	1381	of
O	1382	1390	patients
O	1391	1395	with
O	1396	1399	IHC
O	1400	1401	1
O	1401	1402	+
O	1402	1403	/
O	1403	1404	2
O	1404	1405	+
O	1406	1410	HER2
O	1410	1411	-
O	1411	1421	expressing
O	1422	1428	tumors
O	1428	1429	,
B-outcome	1430	1431	5
I-outcome	1431	1432	-
I-outcome	1432	1436	year
I-outcome	1437	1440	DFS
O	1441	1444	was
B-iv-bin-percent	1445	1447	77
I-iv-bin-percent	1447	1448	.
I-iv-bin-percent	1448	1449	2
I-iv-bin-percent	1449	1450	%
O	1451	1453	in
O	1454	1464	vaccinated
O	1465	1473	patients
O	1474	1475	(
O	1475	1476	n
O	1477	1478	=
B-iv-bin-abs	1479	1481	76
O	1481	1482	)
O	1483	1489	versus
B-cv-bin-percent	1490	1492	65
I-cv-bin-percent	1492	1493	.
I-cv-bin-percent	1493	1494	7
I-cv-bin-percent	1494	1495	%
O	1496	1498	in
O	1499	1506	control
O	1507	1515	patients
O	1516	1517	(
O	1517	1518	n
O	1519	1520	=
B-cv-bin-abs	1521	1523	78
O	1523	1524	)
O	1525	1526	(
O	1526	1527	P
O	1528	1529	=
O	1530	1531	0
O	1531	1532	.
O	1532	1534	21
O	1534	1535	)
O	1535	1536	.

O	1537	1539	In
O	1540	1548	patients
O	1549	1553	with
O	1554	1560	triple
O	1560	1561	-
O	1561	1569	negative
O	1570	1576	breast
O	1577	1583	cancer
O	1584	1585	(
O	1585	1589	HER2
O	1590	1593	IHC
O	1594	1595	1
O	1595	1596	+
O	1596	1597	/
O	1597	1598	2
O	1598	1599	+
O	1600	1603	and
O	1604	1611	hormone
O	1612	1620	receptor
O	1621	1629	negative
O	1629	1630	)
B-outcome	1631	1634	DFS
O	1635	1638	was
B-iv-bin-percent	1639	1641	77
I-iv-bin-percent	1641	1642	.
I-iv-bin-percent	1642	1643	7
I-iv-bin-percent	1643	1644	%
O	1645	1647	in
O	1648	1658	vaccinated
O	1659	1667	patients
O	1668	1669	(
O	1669	1670	n
O	1671	1672	=
B-iv-bin-abs	1673	1675	25
O	1675	1676	)
O	1677	1683	versus
B-cv-bin-percent	1684	1686	49
I-cv-bin-percent	1686	1687	.
I-cv-bin-percent	1687	1688	0
I-cv-bin-percent	1688	1689	%
O	1690	1692	in
O	1693	1700	control
O	1701	1709	patients
O	1710	1711	(
O	1711	1712	n
O	1713	1714	=
B-cv-bin-abs	1715	1717	25
O	1717	1718	)
O	1719	1720	(
O	1720	1721	P
O	1722	1723	=
O	1724	1725	0
O	1725	1726	.
O	1726	1728	12
O	1728	1729	)
O	1729	1730	.

O	1731	1734	The
O	1735	1742	overall
O	1743	1752	intention
O	1752	1753	-
O	1753	1755	to
O	1755	1756	-
O	1756	1761	treat
O	1762	1770	analysis
O	1771	1783	demonstrates
O	1784	1786	no
O	1787	1794	benefit
O	1795	1797	to
O	1798	1809	vaccination
O	1809	1810	.

O	1811	1818	However
O	1818	1819	,
O	1820	1823	the
O	1824	1831	results
O	1832	1839	confirm
O	1840	1844	that
O	1845	1848	the
O	1849	1856	vaccine
O	1857	1859	is
O	1860	1864	safe
O	1865	1868	and
O	1869	1876	suggest
O	1877	1881	that
O	1882	1893	vaccination
O	1894	1897	may
O	1898	1902	have
O	1903	1911	clinical
O	1912	1919	benefit
O	1920	1922	in
O	1923	1931	patients
O	1932	1936	with
O	1937	1940	low
O	1941	1945	HER2
O	1945	1946	-
O	1946	1956	expressing
O	1957	1963	tumors
O	1963	1964	,
O	1965	1977	specifically
O	1978	1982	TNBC
O	1982	1983	.

O	1984	1991	Further
O	1992	2002	evaluation
O	2003	2005	in
O	2006	2007	a
O	2008	2018	randomized
O	2019	2024	trial
O	2025	2034	enrolling
O	2035	2039	TNBC
O	2040	2048	patients
O	2049	2051	is
O	2052	2061	warranted
O	2061	2062	.
